Publications by authors named "Colin Vale"
SOHO State of the Art Updates and Next Questions | Choosing and Properly Using a JAK Inhibitor in Myelofibrosis.
Clin Lymphoma Myeloma Leuk
September 2024
Article Synopsis
- * Four JAK inhibitors have been approved to manage MF symptoms, with allogeneic stem cell transplantation as a potential cure for higher-risk patients, although it's risky.
- * Newer JAK inhibitors, like pacritinib and momelotinib, are designed to be more effective for patients with low platelet or red blood cell counts, and ongoing research aims to improve treatment outcomes through sequencing therapies and developing novel combinations.
Myelodysplastic Neoplasms (MDS) have been traditionally studied through the assessment of blood counts, cytogenetics, and morphology. In recent years, the introduction of molecular assays has improved our ability to diagnose MDS. The role of Measurable (minimal) Residual Disease (MRD) in MDS is evolving, and molecular and flow cytometry techniques have been used in several studies.
View Article and Find Full Text PDFAcute myeloid leukemia (AML) patients undergoing consolidation chemotherapy with intermediate or high-dose cytarabine (IDAC/HiDAC) are often placed on prophylactic antibacterials. This practice is largely based on the benefits of prophylaxis (PPX) during induction chemotherapy. However, recent concerns regarding antibacterial prophylaxis have emerged including risk of Clostridioides difficile colitis, medication toxicities, and the potential for fostering multidrug-resistant pathogens.
View Article and Find Full Text PDFThe therapeutic armamentarium for multiple myeloma has grown significantly over the past decade. We characterized ongoing multiple myeloma clinical trials utilizing ClinicalTrials.gov .
View Article and Find Full Text PDF